Diabetes drug shows promise for repairing damaged nerves

NCT ID NCT07706088

Not yet recruiting Disease control Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial investigates whether tirzepatide, a medication already used for diabetes and weight loss, can help repair nerve damage in people with diabetic peripheral neuropathy. The study includes 40 adults with diabetes and nerve pain or numbness. Researchers will measure nerve health using advanced imaging and nerve tests to see if tirzepatide improves nerve structure and function beyond standard diabetes care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide, a dual GLP-1 and GIP receptor agonist, given as a weekly injection
What this could lead to: If it works, this could point toward a treatment that not only controls blood sugar but also repairs damaged nerves in people with diabetes.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The drug may cause side effects like nausea or vomiting, and nerve repair may not be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic polyneuropathy neuropathy, small fiber Small Fiber Neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE MELLITUS NEUROPATHY, SMALL FIBER

More trials for these conditions

Other studies related to the condition(s) this trial covers.